RxDoctor Payments Data

Randall Raine, DO

Internal Medicine · Venice, FLNPI 1588636013

Payments from drug & device makers

$285in general payments, 2019–2025

Across 13 payments — averaging $21.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$81
  • Novo Nordisk$70
  • Dexcom, Inc.$40
  • GSK$30
  • Lilly USA, LLC$25
  • Exact Sciences$23
  • plus $17 from 1 others

What the payments were for

  • Food & beverage$285100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Coloplast1$81
Novo Nordisk5$70
Dexcom, Inc.2$40
GSK2$30
Lilly USA, LLC1$25
Exact Sciences1$23
Merck1$17

How this compares

$285 in reported general payments places this provider in the 45th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$172,416
Medicare patients
537
Services billed
1,831

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban130$143,697
OzempicSemaglutide60$70,989
MounjaroTirzepatide44$65,859
JardianceEmpagliflozin34$49,250
FarxigaDapagliflozin Propanediol44$44,132
TriumeqAbacavir/Dolutegravir/Lamivudi11$40,921
XareltoRivaroxaban19$26,212
JanuviaSitagliptin Phosphate26$22,223
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$10,425
MyrbetriqMirabegron15$10,198
TrintellixVortioxetine Hydrobromide11$6,817
Venlafaxine Hcl ErVenlafaxine Hcl67$5,863
Atorvastatin Calcium452$4,238
Levothyroxine Sodium418$4,159
Rosuvastatin Calcium287$3,511

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$70$70,98960 claims
Lilly USA, LLCMounjaro$25$65,85944 claims
MerckJanuvia$17$22,22326 claims
GSKAnoro Ellipta$30$10,42511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Venice

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →